EPO Staff, Users List Priorities For Incoming President 19/06/2018 by Dugie Standeford for Intellectual Property Watch Leave a Comment As the European Patent Office (EPO) prepares to welcome a new president, staff members and patent practitioners are setting out their priorities and suggestions for the newcomer, António Campinos. Topping the list for patent examiners is ending the contentious relationship between management and employees. Patent attorneys and litigators, meanwhile, want to see more attention paid to creating a fair balance between the speed of patent grants and patent quality.
EU Governments Reach Negotiating Stance On Copyright Reform 25/05/2018 by Dugie Standeford for Intellectual Property Watch 1 Comment European Union member states today reportedly agreed on their negotiating position on the proposed copyright directive, and early reactions are unenthusiastic.
Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford for Intellectual Property Watch 17 Comments For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say.
Ukraine Eyes Patent Law Reform After Civil Society Push On Medicines Access 30/04/2018 by Dugie Standeford for Intellectual Property Watch 14 Comments Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.
Medicines For Europe Conference Tackles Top Legal Issues For Generic Drug Makers 26/04/2018 by Dugie Standeford for Intellectual Property Watch 2 Comments LONDON — Biosimilars, supplementary protection certificates and European Patent Office patent quality are among the priority issues for the generic drug manufacturing sector, speakers said Wednesday at a Medicines for Europe conference.
US Supreme Court Rules Inter Partes Review Legal 24/04/2018 by Dugie Standeford for Intellectual Property Watch Leave a Comment United States Patent and Trademark Office inter partes reviews are legal and do not violate Article III of the Constitution or the 7th Amendment, the US Supreme Court said today. While the decision was expected, practitioners before the USPTO’s Patent Trial and Appeal Board can now rest easy, as one patent lawyer put it.
Decision In US Inter Partes Review Case Coming But Outcome Seen As “Highly Uncertain” 06/04/2018 by Dugie Standeford for Intellectual Property Watch 1 Comment The United States Supreme Court is likely to affirm the constitutionality of US Patent and Trademark Office inter partes reviews when it rules in the closely watched matter of Oil States Energy Services, LLC v. Greene’s Energy Group LLC, according to Michael Best & Friedrich intellectual property attorney Marshall Schmitt. The end result of the decision, however, is hard to predict, he said.
Federal Circuit Ruling in Oracle v. Google Could Affect Global Software Industry 03/04/2018 by Dugie Standeford for Intellectual Property Watch Leave a Comment Google’s use of 37 of Oracle’s Java application programming interface (API) packages in its Android operating system infringed Oracle patents and copyright, the US District Court for the Federal Circuit (CAFC) said on 27 March. The latest decision in the long-running case was not unreasonable but could stifle software innovation, lawyers said.
Key Drug Innovations Often Don’t See Market Rewards, Academic Says 15/03/2018 by Dugie Standeford for Intellectual Property Watch Leave a Comment There is little evidence that more innovative or therapeutically valuable pharmaceutical products are rewarded, or that patents are the best way to do so, Economics Professor Margaret Kyle of the Centre d’économie industrielle of Mines ParisTech says in an upcoming study for the Review of Industrial Organization.
USPTO Rejects Use Of Tribal Sovereign Immunity In Allergan Patent Deal 01/03/2018 by Dugie Standeford for Intellectual Property Watch 1 Comment Native American tribes’ sovereign immunity can’t be used to avoid inter partes review (IPR) of patent validity, the US Patent and Trademark Office Patent and Appeal Board (PTAB) has ruled in a first-of-its-kind case.